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Breast cancer is the most frequently 
diagnosed type of cancer in women 
worldwide. Both the development 
and progression of breast cancer are 
related to tumour evasion of the im-
mune system through a process called 
cancer immune-editing, in which reg-
ulatory lymphocytes play an import-
ant role. The infiltration of Treg cells 
in patients with breast cancer has 
been proposed as an independent 
unfavourable prognostic factor. In the 
present study, we aimed to evaluate 
the percentages of the Treg cell pop-
ulations in the peripheral blood of pa-
tients with breast cancer with respect 
to progesterone receptor expression.
Peripheral blood samples were collect-
ed from 27 patients with breast can-
cer treated in the Clinical Department 
of Breast Cancer and Reconstructive 
Surgery of the Professor Franciszek 
Lukaszczyk Oncological Centre, Byd-
goszcz. Flow cytometry was used to 
evaluate the percentage of CD25+/
FOXP3+/CD127 (–/low) T cells within 
CD3+/CD4+ T cells. 
The presence of CD25+/FOXP3+/
CD127 (–/low) T cells within CD3+/
CD4+ T cells was identified in all the 
examined blood samples. A statisti-
cally significantly higher percentage of 
CD25+/FOXP3+/CD127 (–/low) T cells 
within CD3+/CD4+ T cells was ob-
served in progesterone receptor 
(PR)-negative breast cancer patients 
when compared to PR-positive breast 
cancer patients.
The observed high percentage of 
CD25+/FOXP3+/CD127 (–/low) T cells 
within CD3+/CD4+ T cells in PR (–) 
breast cancer patients when com-
pared to PR (+) breast cancer patients 
seems to confirm the unfavourable 
prognostic significance of these cells 
in breast cancer patients. This may in-
dicate a rationale for combining stan-
dard oncological treatment in breast 
cancer patients with Treg-depleting 
therapy.
Key words: breast cancer, Treg lym-
phocytes, progesterone receptors.
Contemp Oncol (Pozn) 2018; 22 (4): 236–239
DOI: https://doi.org/10.5114/wo.2018.80038
Original paper
Analysis of Treg cell population  
in patients with breast cancer  
with respect to progesterone 
receptor status
Konrad Dziobek1, Marta Biedka2,3, Tomasz Nowikiewicz4,  
Maria Szymankiewicz5, Ewelina Łukaszewska6, Magdalena Dutsch-Wicherek5
1Department of Oncological Gynecology, Maria Sklodowska-Curie Memorial Cancer  
 Centre and Institute of Oncology, Krakow Branch, Krakow 
2Department of Radiotherapy, Professor Franciszek Lukaszczyk Oncology Center  
 in Bydgoszcz, Poland 
3Department of Oncology and Brachytherapy, Ludwik Rydygier Collegium Medicum  
 in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland 
4Clinical Department of Breast Cancer and Reconstructive Surgery, Professor Franciszek  
 Lukaszczyk Oncology Center in Bydgoszcz, Poland 
5Department of Oncology, Radiotherapy, and Gynecologic Oncology, Ludwik Rydygier  
 Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz,  
 Poland 
6 Department of Pathology, Professor Franciszek Lukaszczyk Oncology Center 
in Bydgoszcz, Poland
Introduction
Breast cancer is the most frequently diagnosed type of cancer in wom-
en and the second leading cause of death from cancer for women world-
wide. The prognosis for breast cancer is determined by age, lymph node 
involvement, tumour grade, nuclear expression of estrogen receptor (ER), 
progesterone receptor (PR), and membrane expression of human epidermal 
growth factor receptor 2 (HER2) [1, 2]. The development and progression 
of the cancer is related to tumour evasion of the immune system through 
a process called cancer immune-editing consisting of three phases: elimina-
tion, equilibrium, and evasion. During the elimination phase, also called im-
munosurveillance, innate and adaptive immune responses cooperate to de-
stroy the growing tumour cells before they become clinically apparent. In the 
equilibrium phase rare tumour cell variants that have escaped elimination 
outgrow. The cancer cells that have acquired resistance to the elimination 
enter the escape phase. During this phase cancer cells continue to grow and 
expand in an uncontrolled manner, enabled by several mechanisms includ-
ing development of a suppressive cancer microenvironment. One if those 
mechanisms is recruitment of T regulatory cells exerting a regulatory effect 
on the immune system. At this phase the tumour becomes clinically appar-
ent. Among the tumour-infiltrating lymphocytes (TILs) in breast cancer pa-
tients are regulatory T cells (Treg), which are identified by the nuclear factor 
forkhead box P3 (FOXP3) [3]. FOXP3+ TILs are correlated with a high risk of 
negative clinicopathological factors, such as ER negativity and high tumour 
grade [4, 5]. Treg cell infiltration of breast cancer has been considered as an 
independent negative prognostic factor [6, 7]. However, in a study conducted 
by West et al. with a cohort of 175 women with estrogen-receptor-negative 
breast cancers, FOXP3+ TILs were demonstrated as an independent positive 
prognostic factor in ER-negative breast cancer [8]. Tylor et al. demonstrat-
ed that the recruitment of Tregs to the cancer microenvironment inhibits 
an effective antitumour immune response, and in patients with claudin-low 
breast cancer, these tumours were found to be highly enriched with Tregs 
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[9]. On the other hand, FOXP3+ TILs were also identified 
as an independent factor for improved survival and pro-
gression-free survival in triple-negative breast cancer [10]. 
In the present study, we aimed to evaluate the percent-
ages of Treg cell populations in the peripheral blood of pa-
tients with breast cancer with respect to progesterone-re-
ceptor status.
Material and methods
The study included 27 patients who were treated surgi-
cally for breast cancer in 2017 in the Clinical Department 
of Breast Cancer and Reconstructive Surgery of the Lu-
kaszczyk Oncological Centre, Bydgoszcz, Poland.
Patients were treated in line with the accepted man-
agement standard; in all cases, this involved combination 
treatment. All 27 patients underwent surgical treatment 
with radiotherapy of the breast. In every case, breast-con-
serving treatment (BCT) with sentinel lymph node biopsy 
(SLNB) was applied [11, 12]. Each patient underwent radical 
surgery. According to current recommendations, this in-
volved removal of the tumour within the limits of healthy 
tissues (no ink on the tumour) [11, 12], and this was con-
firmed by the histopathological examination of the state 
of surgical margins. The SLNB procedure identified the 
patients without the presence of metastatic lesions in 
the axillary (cN0 group). The pre-operative assessment 
of the clinical condition required for this purpose includ-
ed a physical examination of the patients supplemented 
by an ultrasound examination of the axilla. The isotope 
method was used to identify the sentinel lymph node. The 
surgical procedure was preceded by lymphoscintigraphy 
using 99mTc radionuclide with 75–100 MBq activity on the 
albumin carrier (Nanocol). The isotopic marker was admin-
istered intradermally at the margin of the nipple envelope 
(in the breast quadrant where the primary change was 
located) approximately 2–3 hours before the surgery. For 
intraoperative identification of places of increased accu-
mulation of radiotracers in the axillary cavity, and to mea-
sure the radiation value of the lymph nodes, a handheld 
gamma ray detector was used. The lymph node with the 
highest level of radiation was considered the sitter node 
sought during the surgical procedure. According to the 
“10% rule” established by Martin et al. [13], lymph nodes 
displaying elevated radiotracer collection greater than 
10% of the radiation value obtained for the sentinel node 
(nodes of the heart) were also removed.
The patient’s consent was obtained in each case. Ad-
ditionally, approval for the research program was granted 
by the Ethical Committee of the Nicolaus Copernicus Uni-
versity Ludwig Rydygier Collegium Medicum in Bydgoszcz 
(KBET/364/B/2015).
All the patients in our study had an invasive ductal 
breast cancer. From these patients two groups were select-
ed: 19 patients with invasive breast cancer luminal type A: 
ER (+) PR (+) HER (–), Ki 67 until 15% and eight patients 
with non-luminal (HER-positive) invasive breast cancer 
ER (–) PR (–) HER (+), Ki 67 in each case, according to Saint 
Gallen Consensus 2017. No statistically significant differ-
ences in tumour stage, lymph node status, tumour grade, 
and HER status were observed between the two groups 
of patients. The characteristics of the patient groups are 
presented in Table 1. From each of the patient peripheral 
blood samples were collected one day before the surgical 
procedure.
Flow cytometry
The samples for the cytometric evaluation of the Treg 
cell population in the whole blood of breast cancer patients 
(luminal A type) were prepared using Becton Dickinson 
reagents, according to the manufacturer’s instructions. At 
first, the following antibodies for the detection of surface 
antigens were added to 100 μl peripheral blood collected 
on EDTA: 5 μl CD3 APC-Cy7, 20 μl CD4 FITC, 20 μl CD25 
Table 1. Characteristics of the patient group
Characteristic Number of patients (%)
Age 57 years (range: 31–64)




Lymph node status according to TNM 2010
Without lymph node involvement N0 22 (81)
With lymph node involvement N1 5 (19)
Tumour differentiation grade
Grade 1 1 (3)
Grade 2 25 (92)
Grade 3 1 (3)
Histopatological assessment
Carcinoma ductale 27 (100)
After operation margin
> 1 cm 27 (100)
< 1 cm 0 (0)
Hormonal status
ER positive 19 (70)
ER negative 8 (30)
PR positive 19 (70)
PR negative 8 (30)
HER status
HER positive 8 (30)
HER negative 19 (70)
Ki-67 expression
< 10% 0 (0)
10–15% 19 (70)
> 20% 8 (30)
Type of treatment





APC, 5 μl CD127 PerCP-Cy5.5, and 5 μl CD194 PE-Cy7. After 
a 20-min incubation with mAbs (in the dark at room tem-
perature – RT), the cells were washed with 2 ml of fetal 
bovine serum (FBS) buffer and centrifuged for 10 min at 
250 × g. The obtained cell pellet was fixed with 2 ml of 
freshly prepared 1 × buffer A (for 10 min at RT) and centri-
fuged for 5 min at 500 × g. The cells were then washed with 
2 ml of FBS buffer (5 min, 500 × g) and permeabilised with 
0.5 ml of freshly prepared buffer C (for 30 min in the dark 
at RT). After two further washing steps (2 ml FBS; 5 min, 
500 × g), the cells were stained with 20 μl of anti-human 
nuclear FOXP3 PE antibody for 30 min in the dark at RT. After 
two additional washing steps, the cells were suspended in 
0.5 ml of FBS buffer and analysed using BD FACS Canto II 
flow cytometer and BD FACS Diva Software (Becton Dickin-
son). In each sample, 15,000–25,000 CD3+/CD4+ cells were 
collected, among which the percentage of Treg lymphocytes 
was determined, according to the gating strategy described 
in the additional materials in the article by Santegoets et al. 
[14]. Treg cells were considered to be CD3+/CD4+/CD25+/
FOXP3+/CD127 (–/low).
Statistical analysis
The distribution of variables in the study groups of the 
women was checked with the use of the Shapiro-Wilk test. 
The statistical significance between the groups was deter-
mined by the Kruskal-Wallis test, one-way analysis of vari-
ance by ranks. The Mann-Whitney U test was then used as 
applicable. All statistical analyses were carried out with Sta-
tistica 8.0 software (StatSoft Inc., Tulsa, OK, USA). A p-value 
< 0.05 was considered indicative of statistical significance.
Results
The CD3+/CD4+/CD25+/FOXP3+/CD127 (–/low) T cells 
were identified in all the examined blood samples derived 
from the patients with breast cancer after the surgical pro-
cedure. The statistically significantly higher percentage of 
CD25+/FOXP3+/CD127 (–/low) T cells within CD3+/CD4+ 
T cells was observed in PR (–) breast cancer patients fol-
lowing surgery when compared to PR (+) breast cancer 
patients following surgery (Fig. 1).
Discussion
The loss of PR may reflect a change to a more aggres-
sive tumour behaviour [15]. PR is an ER-regulated gene 
that mediates the effects of progesterone on the develop-
ment of mammary glands in physiology and is involved in 
the development of breast cancer. Increased breast cancer 
incidence is identified in patients after combined estrogen 
and progesterone hormone replacement therapy com-
pared to estrogen therapy alone [16]. ER-positive/PR-neg-
ative metastatic tumours are observed to have a more ag-
gressive course and are associated with a reduced overall 
survival compared to those preserving PR [17].
In the present study, statistically significantly higher 
CD25+/FOXP3+/CD127 (–/low) T cells within CD3+/CD4+ 
T cells were identified in the patients with PR(–) breast 
cancers compared to those with PR(+) breast cancers. 
Moreover, in a meta-analysis, Wang et al. demonstrated 
that Treg cell infiltration was more prominent in breast 
cancer patients with ER (+) and PR (–) tumours. The loss of 
PR expression is correlated with more aggressive tumour 
behaviour and a reduced overall patient survival rate [18, 
19]. In the presented study the number of the patients 
with PR-negative tumours is small, which might impair 
the statistics; however, the general trend in the presence 
of CD25+/FOXP3+/CD127 (–/low) T cells within the CD3+/
CD4+ T cell population in PR (–) invasive breast cancer pa-
tients is documented.
Thus, it seems that patients with breast cancer might 
benefit from the elimination of Treg cells. Dendritic cells 
have been used in the development of antitumour vac-
cines because they trigger the antitumour immunity in 
cancer; however, this response was not sufficient to induce 
tumour regression. It has been proposed that this is due 
to the expansion of immunosuppressive cells such as Treg 
cells. In an experimental study by Ayala et al. [18], FOXP3 
blockade improved the efficacy of dendritic cell vaccines 
by inhibiting Treg cells and the direct antitumour effect. 
It was thus proposed that FOXP3 blockade can neutralise 
the immunosuppressive tumour microenvironment and 
switch the antitumour immune response [18]. 
Conclusions
In conclusion, the subpopulation of regulatory T cells 
in our study were related with the loss of PR expression, 
an unfavourable prognostic factor. Our study, together 
with other reports, therefore seems to confirm a rationale 
for combining the standard oncological treatment with 
Treg-depleting therapy. 
The authors declare no conflict of interest.
Fig. 1. The percentage of CD25+/FOXP3+/CD127 (–/low) T cells 
within CD3+/CD4+ T cells in patients with progesterone receptor 
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p < 0.05
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